By the time most Indian eczema patients see a qualified dermatologist for the first time, they have already been on years of unprescribed topical steroids. A combination of OTC pharmacy sales, “ayurvedic” creams that secretly contain clobetasol, and so-called fairness creams marketed for everything from acne to pigmentation has produced a population-scale public health problem the Indian dermatology community has named several times but has not been able to fix: topical steroid withdrawal (TSW), also called Red Skin Syndrome.
This is not a niche issue. The Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) has been petitioning the Central Drugs Standard Control Organization (CDSCO) since 2014 to put clobetasol- and betamethasone-containing fixed-dose combinations under prescription-only control. The Indian Journal of Dermatology, Venereology and Leprology (IJDVL) has published case series and audits documenting the exact named-brand creams driving the problem.
This article is the long-form companion to the Eczema in India pillar guide. The pillar covers eczema as a whole. This piece goes deep on the single biggest reason Indian eczema patients get worse the longer they treat themselves — chronic unsupervised topical steroid use — and gives a realistic recognition-and-recovery protocol patients and clinicians can actually use.
What TSW Actually Is
Topical steroid withdrawal is a distinct adverse skin reaction following prolonged use of moderate-to-potent topical corticosteroids, characterised by burning erythema, edema, oozing, scaling and rebound flare on tapering or stopping. It is not the same as a worsening eczema flare. It is not the same as contact dermatitis. It is not the same as a rebound on stopping oral steroids.
The pathophysiology is incompletely understood but the dominant hypotheses are:
- Vasodilatory rebound — chronic steroid causes downregulation of vasoconstrictive responses; on stopping, blood vessels dilate dramatically (burning red sleeve)
- Loss of feedback control of cortisol and glucocorticoid receptors in the skin
- Skin barrier dysfunction with elevated trans-epidermal water loss
- Microbiome shift with Staphylococcus aureus and Malassezia overgrowth
- Nitric oxide release from previously suppressed pathways
The clinical fingerprint, regardless of mechanism, is consistent and recognisable.
The Indian OTC Steroid Pipeline — Named Brands Driving TSW
The reason TSW is overrepresented in India is that potent topical steroids in fixed-dose combinations are sold over the counter at most chemists without enforcement of the prescription-only requirement. The most clinically documented offending products are:
Triple- and Quad-Combinations (Steroid + Antifungal + Antibiotic)
| Brand | Steroid Component | Why Patients Use It | Why It’s a Problem |
|---|---|---|---|
| Panderm Plus | Clobetasol propionate 0.05% | “Itchy rash” — eczema, ringworm, perianal itch | Super-potent steroid on undiagnosed tinea creates tinea incognito; long use causes TSW |
| Cosvate-GM, Cosvate-GG | Clobetasol propionate 0.05% | Generic “skin infection” | Same as above |
| Quadriderm RF | Beclomethasone dipropionate 0.025% | “Rash, fungal infection” | Moderate steroid on chronic use; misused for years |
| Betnovate-C, Betnovate-N | Betamethasone valerate 0.1% | “Itchy patch” | Potent steroid; widely abused |
| Tenovate-M, Tenovate-GN | Clobetasol propionate 0.05% | “Skin infection” | Super-potent steroid in combination |
These combinations were specifically designed for very short-term use in mixed superficial infection. In practice, patients use them for months to years for any itchy condition — a use pattern that produces the maximum TSW risk.
So-Called Fairness / Brightening Combinations
| Brand | Composition | Marketing | Real Risk |
|---|---|---|---|
| Skin Lite | Hydroquinone + tretinoin + mometasone | ”Brightening, melasma” | Steroid component drives dependence + TSW on face |
| Melalumin | Hydroquinone + tretinoin + steroid | ”Pigmentation” | Same |
| Melalite Forte | Hydroquinone + tretinoin + mometasone | ”Spot correction” | Same |
| Triluma (and generics) | Hydroquinone 4% + tretinoin 0.05% + fluocinolone 0.01% | Prescription only — but sold OTC at many chemists | Standard 8-week protocol; chronic use causes facial TSW |
The brightening / fairness pipeline and the eczema steroid pipeline are the same pharmacological problem with two marketing front-ends. The post-acne pigmentation cycle that drives some Indian patients onto these creams is the same cycle covered in the post-acne dark spots and PIH on Indian skin guide — but the standard PIH protocol there uses tretinoin, niacinamide, azelaic acid and sunscreen, not chronic steroid.
Single-Molecule Steroids Misused Long-Term
Betnovate (betamethasone valerate 0.1%), Tenovate (clobetasol propionate 0.05%) and Dermovate sold without prescription on chronic use are all routine drivers of TSW in Indian OPD case series.
What the Lab Tests Have Found in “Ayurvedic” Creams
Multiple independent laboratory investigations of OTC “ayurvedic” and “herbal” creams in India have repeatedly identified undeclared corticosteroids — most commonly clobetasol propionate, sometimes betamethasone valerate, occasionally hydrocortisone or triamcinolone.
The pattern is consistent enough that the IADVL has issued patient advisories specifically warning about herbal-labelled creams used for eczema, psoriasis, pigmentation and acne. The IJDVL has published case series of patients who developed steroid-dependent dermatitis and TSW after years of using creams they believed were free of allopathic ingredients.
The clinical fingerprint these creams produce is identical to any other clobetasol abuse:
- Days 1 to 14: dramatic improvement, patient believes the product works
- Weeks 2 to 8: dependency — re-application needed every 2 to 3 days to maintain
- Months 3+: skin atrophy, telangiectasia, perioral dermatitis, sometimes acneiform eruption
- On stopping: severe rebound flare, burning, redness, often misdiagnosed as “the original problem coming back”
The parallel with the ayurveda regulatory gap is the same pattern documented in the Giloy hepatitis Mumbai 2021 AYUSH cases and the broader Giloy brand purity and adulteration lab data — third-party lab testing of AYUSH-labelled products in India repeatedly turns up undisclosed actives, heavy metals or adulteration.
Safer rule: use ayurvedic creams only from manufacturers that publish per-batch third-party lab certificates that screen explicitly for corticosteroids, heavy metals and hydroquinone. If the product is sold with marketing claims of dramatic results in 7 days for chronic eczema, default assumption should be that it contains an undeclared steroid.
CDSCO and IADVL — What Has Actually Been Banned
The regulatory record is messier than the campaigns suggest:
- 2016 onwards: CDSCO has placed several specific fixed-dose combinations on Schedule H (prescription-only), and asked state drug controllers to enforce.
- 2018, 2020, 2023: IADVL TSW awareness campaigns and petitions to CDSCO for Schedule H or Schedule X status for all clobetasol- and betamethasone-containing combinations.
- State-level action: Maharashtra FDA, Kerala drug controller and a few others have intermittently raided chemists for OTC sale of these combinations.
- Enforcement: in practice, patchy. The same combinations are still dispensed at most chemists across India on verbal request.
Bottom line for patients: the law restricts these products on paper. The retail reality is they are still on shelves and behind counters. Do not assume legality equals safety.
How to Recognise TSW — A Practical Diagnostic Framework
The single most useful diagnostic question is: “How does the current flare compare to your original disease?”
TSW is not a worsening of the original eczema. It is a different beast in distribution and sensation.
Pattern Recognition
| Feature | Original Eczema Flare | Contact Dermatitis | TSW (Red Skin Syndrome) |
|---|---|---|---|
| Onset | Hours to days after trigger | Hours to days after allergen contact | Days to weeks after stopping or tapering chronic steroid |
| Colour | Patchy red, dry, scaly | Sharply confined red plaque | Bright burning red “sleeve” — wrist to elbow, ankle to knee, around mouth and eyes |
| Distribution | Classic eczema sites — folds, neck, face | Limited to contact area | Often beyond original eczema area; includes skin that was never affected before |
| Sensation | Itch dominant | Itch + sometimes burning | Burning and stinging dominant; itch secondary |
| Sweating | Normal | Normal | Impaired or absent in affected skin |
| Response to steroid | Predictable improvement in 3 to 7 days | Improves with steroid | Brief suppression then escalating dose needed |
| Photos pattern | Old patient photos look similar | New, time-locked | New pattern not seen before |
| Shedding | Mild flaking | Mild | Sheets of skin, “elephant skin” appearance |
Time-Locked Red Flags
A patient is very likely in TSW if all four of these are true:
- Used a moderate-to-potent topical steroid (or unknown ayurvedic / fairness cream) for more than 12 weeks continuously, or repeatedly for months to years.
- The current flare started or dramatically worsened within 2 to 8 weeks of stopping or trying to taper.
- Burning and stinging are now dominant over itch.
- The skin pattern goes beyond the area you originally treated.
A Realistic Recovery Protocol — What Actually Works
Recovery is hard. It is not linear. The protocol below reflects what dermatologists familiar with TSW use in Indian practice, drawn from IADVL position statements and global TSW management consensus.
Step 1 — Total Steroid Stop, Prepared for a Bad 4 to 8 Weeks
This is the hardest step. Tapering schedules have been tried but the bulk of clinical experience suggests a clean stop produces a clearer recovery curve than a slow taper that prolongs the dependency. Patients should be warned the first 4 to 8 weeks will look and feel worse.
Step 2 — Non-Steroidal Anti-Inflammatory Topicals
- Tacrolimus ointment 0.1% (Tacroz Forte, Protopic) — calcineurin inhibitor, twice daily, on the affected skin. Burning on application for the first 1 to 2 weeks is expected.
- Pimecrolimus cream 1% (Elidel) — milder, better for the face, eyelids and very thin skin.
- Crisaborole 2% or difamilast — PDE4 inhibitors, less commonly used in India because of price. See the difamilast (Adquey) India guide for the comparative cost picture.
Step 3 — Heavy Barrier Repair and Symptomatic Care
- White petrolatum (plain Vaseline, ₹150–₹300 per 450g) applied 3 to 5 times a day. Cheapest and most effective barrier.
- Ceramide-rich creams (Atogla, Venusia Max, CeraVe parallel import).
- Cool compresses for the burning.
- Oral antihistamines — hydroxyzine or cetirizine at night for sleep.
- Treat Staphylococcus aureus colonisation — twice-weekly dilute bleach baths (0.005%, one cap of Domex/Sanifresh in 40 L water), short cloxacillin or cefadroxil course if frankly infected.
Step 4 — Systemic Therapy for the Worst Phase
- Short cyclosporine course (2.5–5 mg/kg/day, 3–6 months) — gets the patient through the worst burn phase. Monitor BP and creatinine.
- Methotrexate (7.5–15 mg per week) — for chronic moderate disease.
- JAK inhibitors — upadacitinib (₹6,000–₹12,000/month Indian generic) or baricitinib (₹3,000–₹8,000/month) for severe refractory disease. Need monitoring bloodwork.
- Dupilumab is sometimes used for severe TSW with overlapping atopic dermatitis. Cost is the limiter; see the cost reality in the Dupixent India access guide.
Step 5 — Long-Term Maintenance
Once skin stabilises, the patient stays on calcineurin inhibitors as needed, with strict avoidance of any topical steroid that is not specifically dermatologist-prescribed for a brief flare. Many TSW survivors choose to avoid topical steroids permanently — which is a reasonable choice, since calcineurin inhibitors and emollient therapy can carry most cases.
What Not To Do
- Do not “just stop everything and let the skin heal.” Aggressive steroid stop without any anti-inflammatory therapy produces months of unnecessary burning.
- Do not restart the original combination cream because the rebound looks bad. This is the trap that creates years-long TSW.
- Do not chase another ayurvedic cream, especially not one with dramatic results promised. The base-rate of undeclared steroid in those products is high.
TSW and the Indian Healthcare System — A Practical Reality
Indian dermatologists are not uniformly trained in TSW recognition. Many will default to “your eczema is worsening” and prescribe more steroid. Many GPs and chemists have no concept of TSW.
If you suspect TSW:
- Bring every cream you have ever used to the consultation. Brand names matter more than generic recall.
- Bring photos of the original eczema and the current state — pattern change is the key clue.
- Ask the dermatologist explicitly whether they consider TSW or steroid-dependent dermatitis as a possibility, and whether they would consider a calcineurin-inhibitor-led protocol.
- Tertiary referral centres that publish on TSW include AIIMS Delhi, PGI Chandigarh, CMC Vellore, and a handful of academic departments at JIPMER, KMC Manipal and KEM Mumbai.
The pattern of OTC chemist-sold steroids creating downstream skin disease is the same pattern that drives the misuse described in the acne treatment ladder for India. Most Indian skin problems do not start with a dermatologist — they start with a chemist or a quack — and TSW is the worst long-term cost of that funnel.
Mental Health and TSW — The Hidden Burden
TSW is uniquely psychologically punishing. The skin pattern is disfiguring, the burning is constant, sleep is destroyed, and recovery takes 1 to 3 years. Patients describe loss of identity, depression, sometimes suicidal ideation. There is overlap with the burnout-and-somatic-skin pattern documented in the Indian IT sector depression and burnout piece.
Practical recommendations:
- Sleep hygiene is non-negotiable — TSW recovery without sleep is much slower.
- Cognitive behavioural therapy for the itch-scratch-shame cycle is helpful and largely missing from Indian dermatology referral patterns.
- Online TSW communities (ITSAN, Reddit r/TSW) provide useful patient-to-patient knowledge but the medical content varies wildly in quality.
Sources and References
- Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) — Position statement on topical corticosteroid misuse and triple-combination creams
- Indian Journal of Dermatology, Venereology and Leprology (IJDVL) — Case series and audits on topical steroid misuse and TSW, 2014–2024
- Central Drugs Standard Control Organization (CDSCO) — Notifications on fixed-dose combinations and Schedule H classification
- Drugs and Cosmetics Act and Rules — Restrictions on prescription-only sale
- National List of Essential Medicines (NLEM) of India — Topical corticosteroid potency classes
- ITSAN (International Topical Steroid Awareness Network) — Patient-facing TSW recognition resources
- British Journal of Dermatology — Topical steroid withdrawal review, 2015 and 2021
- American Academy of Dermatology — Guidelines on topical corticosteroid use
- Sanofi India — Dupilumab prescribing information
- Indian generic JAK inhibitor data — Sun Pharma, Cipla, Lupin upadacitinib and baricitinib launches
Medical Disclaimer: This article is for informational purposes only and is not medical advice. Topical steroid withdrawal is a serious medical condition that requires individualised dermatology care. Do not stop, taper, or change any prescribed topical or oral medication on your own based on this content. If you suspect TSW, secondary infection, or severe flare, see a dermatologist in person, preferably at a centre with documented experience in TSW management. Reviewed by Fittour India Editorial Team in line with current IADVL and CDSCO positions on topical corticosteroid misuse.